Clinical Trial Objectives, page-21

LET'S NOT FORGET :
This company has had 42 consecutive quarters of solid growth, high returns on equity, zero debt,
using Sirspheres as only salvage treatment for liver metastatic cancer anyway.
NOTHING to do with first line treatment anyway.
Now the Sirflox trial has shown statistically significant progression free survival in the liver which
was the secondary study endpoint.
Surely this will only benefit the ongoing sales growth of Sirspheres as salvage therapy, as has always
been the case so far.
The failure of the primary study endpoint ( overall survival ) only means that the ridiculously high
valuation the market was putting on the share price was unjustified because the market was expecting
elevation of Sirspheres to first line therapy.
But the company will continue to do well regardless with ongoing growth in sales as salvage therapy.
Also there are further studies to be completed in addition to Sirflox ( such as FOXFIRE ), the results
of which maybe will benefit Sirtex.